This transcript has been edited for clarity.
I'm Dr Neil Skolnik. Today we're going to talk about the consensus report by the American Diabetes Association and the European Association for the Study of Diabetes on the management of hyperglycemia.
A lot has changed in this consensus statement. It covers a lot of ground. We're going to focus today on pharmacologic management.
After lifestyle modifications, metformin is no longer the go-to drug for every patient in the management of hyperglycemia. It is recommended that we assess each patient's personal characteristics in deciding what medication to prescribe. For patients at high cardiorenal risk, refer to the left side of the algorithm and to the right side for all other patients.
Cardiovascular disease. First, assess whether the patient is at high risk for atherosclerotic cardiovascular disease (ASCVD) or already has ASCVD. How is ASCVD defined? Either coronary artery disease (a history of a myocardial infarction [MI] or coronary disease), peripheral vascular disease, stroke, or transient ischemic attack.
What is high risk for ASCVD? Diabetes in someone older than 55 years with two or more additional risk factors. If the patient is at high risk for or has existing ASCVD then it is recommended to prescribe a glucagon-like peptide 1 (GLP-1) agonist with proven CVD benefit or an sodium-glucose cotransporter 2 (SGLT2) inhibitor with proven CVD benefit.
For patients at very high risk for ASCVD, it might be reasonable to combine both agents. The recommendation to use these agents holds true whether the person is at their A1c goal or not. The patient doesn't need to be on metformin to benefit from these agents. The patient with reduced or preserved ejection fraction heart failure should be taking an SGLT2 inhibitor.
Chronic kidney disease. Next up, chronic kidney disease (CKD). CKD is defined by an estimated glomerular filtration rate < 60 mL/min/1.73 m2 or a urine albumin to creatinine ratio > 30. In that case, the patient should be preferentially on an SGLT2 inhibitor. Patients unable to take an SGLT2 for some reason should be prescribed a GLP-1 receptor agonist.
If someone doesn't fit into that high cardiorenal risk category, then we go to the right side of the algorithm. The goal then is achievement and maintenance of glycemic and weight management goals.
Glycemic management. In choosing medicine for glycemic management, metformin is a reasonable choice. You may need to add another agent to metformin to reach the patient's glycemic goal. If the patient is far away from goal, then a medication with higher efficacy at lowering glucose might be chosen.
Efficacy is listed as:
High glucose lowering efficacy: a GLP-1 receptor agonist not already mentioned, metformin, SGLT2 inhibitors, sulfonylureas, thiazolidinediones
Intermediate glucose lowering efficacy: dipeptidyl peptidase 4 (DPP-4) inhibitors
Weight management. For weight management, lifestyle modification (diet and exercise) is important. If lifestyle modification alone is insufficient, consider either a medication that specifically helps with weight management or metabolic surgery.
We particularly want to focus on weight management in patients who have complications from obesity. What would those complications be? Sleep apnea, hip or knee pain from arthritis, back pain — that is, biomechanical complications of obesity or nonalcoholic fatty liver disease. Medications for weight loss are listed by degree of efficacy:
Very high efficacy for weight loss: semaglutide, tirzepatide
High efficacy for weight loss: dulaglutide and liraglutide
Intermediate for weight loss: GLP-1 receptor agonist (not listed above), SGLT2 inhibitor
Neutral for weight loss: DPP-4 inhibitors and metformin
Where does insulin fit in? If the patient presents with a very high A1c, if they are on other medications and their A1c is still not to goal, or if they are catabolic and losing weight because of their diabetes, then insulin has an important place in management.
These are incredibly important guidelines that provide a clear algorithm for a personalized approach to diabetes management.
I'm Dr Neil Skolnik, and this is Medscape.
Images: American Diabetes Association
Medscape Family Medicine © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: New Recommendations for Hyperglycemia Management - Medscape - Nov 14, 2022.